English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduNew research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows that people with difficult-to-treat rheumatoid arthritis who do not have success with JAK inhibitor can achieve success either cycling to other JAKi or switching to a biologic drug.
Tag: Biologic
Ultra-Low Dose Rituximab Controls Disease Activity for Most RA Patients in New Study
New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows the majority of rheumatoid arthritis patients on an ultra-low dose of rituximab maintained low disease activity for up to 4 years, and rarely needed to switch to other biologic drugs.
Biologics Now Most Common Treatment for Children with Systemic JIA, and Many Have Excellent Results
New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows that biologics were the most common initial treatment prescribed to treat systemic juvenile idiopathic arthritis patients in one major registry.